A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

BACKGROUND: Relapsed/refractory (R/R) multiple myeloma (MM) patients and primary plasma cell leukemia (PCL) have an unfavorable prognosis and no effective treatment. This study was designed to assess the safety and preliminary efficacy of a novel anti‐B‐cell maturation antigen (BCMA) chimeric antige...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chunrui, Cao, Wenyue, Que, Yimei, Wang, Qiuxiang, Xiao, Yi, Gu, Chaojiang, Wang, Di, Wang, Jue, Jiang, Lijun, Xu, Hao, Xu, Jinhuan, Zhou, Xiaoxi, Hong, Zhenya, Wang, Na, Huang, Liang, Zhang, Shangkun, Chen, Liting, Mao, Xia, Xiao, Min, Zhang, Wei, Meng, Li, Cao, Yang, Zhang, Tongcun, Li, Jian, Zhou, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943908/
https://www.ncbi.nlm.nih.gov/pubmed/33784005
http://dx.doi.org/10.1002/ctm2.346

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7943908/
https://www.ncbi.nlm.nih.gov/pubmed/33784005
http://dx.doi.org/10.1002/ctm2.346

Ejemplares similares